Medicinal radiochemistry

Theragnostics Strengthens Board of Directors with Key Appointments

Retrieved on: 
Wednesday, August 4, 2021
Medicine, Physical sciences, Health sciences, Medical physics, Medicinal radiochemistry, Radiation therapy, Isotopes, Molecular imaging, Radiopharmaceutical, Radionuclide therapy

LONDON, Aug. 4, 2021 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces today the appointments of Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to its Board.

Key Points: 
  • LONDON, Aug. 4, 2021 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces today the appointments of Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to its Board.
  • Ian Gowrie-Smith, Executive Chairman of Theragnostics, said:"We are very pleased to welcome two high calibre board members to Theragnostics.
  • Ken's extensive knowledge in the clinical development and commercialisation of radiopharmaceuticals is key to the advancement and maturity of Theragnostics.
  • Greg Mullen, Chief Executive Officer of Theragnostics, added:"I am very pleased to have Dennis and Ken with their expertise and track record, join our board.

Theragnostics Strengthens Board of Directors with Key Appointments

Retrieved on: 
Wednesday, August 4, 2021
Medicine, Physical sciences, Health sciences, Medical physics, Medicinal radiochemistry, Radiation therapy, Isotopes, Molecular imaging, Radiopharmaceutical, Radionuclide therapy

LONDON, Aug. 4, 2021 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces today the appointments of Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to its Board.

Key Points: 
  • LONDON, Aug. 4, 2021 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces today the appointments of Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to its Board.
  • Ian Gowrie-Smith, Executive Chairman of Theragnostics, said:"We are very pleased to welcome two high calibre board members to Theragnostics.
  • Ken's extensive knowledge in the clinical development and commercialisation of radiopharmaceuticals is key to the advancement and maturity of Theragnostics.
  • Greg Mullen, Chief Executive Officer of Theragnostics, added:"I am very pleased to have Dennis and Ken with their expertise and track record, join our board.

NorthStar Medical Radioisotopes and GE Healthcare Sign Exclusive U.S. Manufacturing and Distribution Agreement

Retrieved on: 
Tuesday, August 3, 2021
Medical Supplies, Health, Hospitals, General Health, Pharmaceutical, Biotechnology, Medicine, Health sciences, Radiopharmaceuticals, Physical sciences, Medical physics, Medicinal radiochemistry, Medicinal chemistry, Nuclear medicine, GE Healthcare, General Electric, Medical imaging, Radiopharmacology

NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, and GE Healthcare today announced the signing of an exclusive agreement for the manufacturing and distribution of iodine-123 (I-123) capsules in the United States.

Key Points: 
  • NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, and GE Healthcare today announced the signing of an exclusive agreement for the manufacturing and distribution of iodine-123 (I-123) capsules in the United States.
  • This exclusive sales and manufacturing agreement marks NorthStars strong and growing relationship with GE Healthcare, and we look forward to working with the company in meeting the needs of radiopharmacy customers and the patients we all serve, said Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes.
  • GE Healthcare Pharmaceutical Diagnostics imaging agents support three patient procedures every second worldwide across MRI, X-ray/CT, ultrasound and nuclear medicine imaging.
  • GE Healthcare is the $18 billion healthcare business of GE (NYSE: GE).

Council on Radionuclides and Radiopharmaceuticals, Inc. Supports the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021

Retrieved on: 
Tuesday, July 27, 2021
Surgery, Medical devices, Public policy, Government, Healthcare reform, Biotechnology, Other Health, Radiology, Health, Oncology, Physical sciences, Natural sciences, Medicinal radiochemistry, Chemistry, Isotopes, Radiopharmaceuticals, Medicinal chemistry, Nuclear medicine, Radiology, Medicare, Radionuclide, Medicine

The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R.

Key Points: 
  • The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R.
  • 4479, the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 by Congressmen Scott Peters (D-CA), Bobby Rush (D-IL), Neal Dunn (R-FL) and Greg Murphy (R-NC).
  • The FIND Act will ensure that patients have access to precision diagnostic radiopharmaceutical (RP) drugs and promotes continued life-saving innovations in nuclear medicine.
  • The current Medicare reimbursement structure in the outpatient setting packages diagnostic RP drugs into nuclear medicine procedure payments.

Positron Retains Healthcare Advisor I-Square Ventures to Implement Strategy and Expand Market Share

Retrieved on: 
Thursday, July 15, 2021
Medical imaging, Medicinal radiochemistry, Medicine, Positron Corporation, Medical specialties, Clinical medicine, Cardiac PET, Nuclear medicine

Adel Abdullah, President of Positron stated: "Positron is at a significant inflection point and in an ideal position to capitalize on a very positive environment and outlook for PET technology.

Key Points: 
  • Adel Abdullah, President of Positron stated: "Positron is at a significant inflection point and in an ideal position to capitalize on a very positive environment and outlook for PET technology.
  • Expanding our team strategically, and deepening our reach within the nuclear imaging industry, should greatly advance and accelerate our progress.
  • We are very pleased to welcome a group of growth experts led by Dr. Bordoloi to our team at this exciting time for Positron.
  • Positron's PET only system, market position and approach in facilitating the adoption of cardiac PET are substantial advantages to the growth of the market and Positron.

International Isotopes Inc. Announces It Has Acquired Full Ownership Of RadQual LLC

Retrieved on: 
Monday, July 12, 2021
Medicine, Neuroimaging, Medical physics, Medicinal radiochemistry, Medical specialties, Clinical medicine, Radiobiology, International Nuclear Information System, International Atomic Energy Agency, Single-photon emission computed tomography, iNiS, Nuclear medicine

In August 2017, this group of sellers acquired all of the units of RadQual not already held by INIS.

Key Points: 
  • In August 2017, this group of sellers acquired all of the units of RadQual not already held by INIS.
  • With this most recent acquisition, INIS will now own 100% of all outstanding units of RadQual, making RadQual a wholly-owned subsidiary of INIS.
  • RadQual is the premier global developer of quality control products for the nuclear medicine industry, focused principally on SPECT and PET imaging.
  • From RadQual 's inception in 2001, INIS has been the sole contract manufacturer of all RadQual products.

Global Nuclear Imaging Equipment Market Competition Forecast & Opportunities, 2021-2026 - PET Imaging Systems, Gamma Camera Imaging Systems - ResearchAndMarkets.com

Retrieved on: 
Monday, July 12, 2021
Radiology, Health, Medical Supplies, Medical devices, Medical physics, Medicine, Medicinal radiochemistry, Nuclear medicine, Medical specialties, Neuroimaging, Medical imaging, Positron emission tomography, Gamma camera

The "Global Nuclear Imaging Equipment Market, By Type (PET Imaging Systems, Gamma Camera Imaging Systems), By Gamma Camera Imaging Systems, By Application, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Nuclear Imaging Equipment Market, By Type (PET Imaging Systems, Gamma Camera Imaging Systems), By Gamma Camera Imaging Systems, By Application, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Nuclear Imaging Equipment Market stood at USD4.05 billion in 2020 and is expected to grow at a steady CAGR of 6.51% to 2026.
  • The growing focus on personalized medicines is further expected to spur the growth of the Global Nuclear Imaging Equipment Market during the next five years.
  • Nuclear imaging equipment aids in treatment process thereby contributing to increase in the demand for the nuclear imaging equipment market.

SHINE Medical Technologies Closes $150-million Series C-5 Financing to Advance Nuclear Fusion-Based Technologies

Retrieved on: 
Monday, June 28, 2021
Research, Venture capital, Professional services, Alternative energy, Energy, Nuclear, Health, General Health, Science, Medicinal radiochemistry, Physical sciences, Natural sciences, Shine, Physics, Nuclear physics, SHINE Medical Technologies, Radioactive waste, Isotopes in medicine, Isotope, Nuclear medicine, SHINE Medical Technologies, Koch Disruptive Technologies, SHINE MEDICAL TECHNOLOGIES, KOCH DISRUPTIVE TECHNOLOGIES

SHINE Medical Technologies LLC today announced that it has closed a $150-million Series C-5 financing.

Key Points: 
  • SHINE Medical Technologies LLC today announced that it has closed a $150-million Series C-5 financing.
  • The financing will support SHINEs commercialization of its diagnostic and therapeutic medical isotope technologies and position the company for future growth as it works toward developing new fusion-based technology applications.
  • The $150-million Series C-5 financing SHINE closed recently was led by KDT.
  • (Photo: SHINE Medical Technologies)
    KDT is an incredible strategic partner for SHINE as we commercialize both diagnostic and therapeutic medical isotopes, and work towards fusion-based nuclear waste recycling and clean energy production, said Greg Piefer, Chairman and CEO of SHINE.

Global Nuclear Medicine Market Share, Size, Trends, Industry Analysis Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 28, 2021
Pharmaceutical, Health, Oncology, Anatomy, Branches of biology, Medicinal radiochemistry, Nuclear medicine, Radiology, Thyroid, Thyroid disease, Nuclear medicine physician, Internal medicine

The "Nuclear Medicine Market Share, Size, Trends, Industry Analysis Report, By Type; By Modality; By Application; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nuclear Medicine Market Share, Size, Trends, Industry Analysis Report, By Type; By Modality; By Application; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • However, nuclear medicine is increasingly being used in therapeutic procedures for the treatment of cancer and thyroid-related conditions.
  • The different applications of nuclear medicine in the market include thyroid, cardiology, bone metastasis, oncology, neurology, gastroenterology, immunology, and others.
  • Increasing applications in cancer detection and the presence of well-established healthcare infrastructure further increases the demand for Nuclear Medicine in North America.

RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

Retrieved on: 
Tuesday, June 15, 2021
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Health sciences, Medicine, Natural sciences, Radiopharmaceuticals, Medicinal radiochemistry, Medicinal chemistry, Rockefeller family, Venrock, TCG

RayzeBio, Inc., which is discovering and developing a broad pipeline of innovative targeted radiopharmaceutical drugs for cancer, today announced a $108 million Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.

Key Points: 
  • RayzeBio, Inc., which is discovering and developing a broad pipeline of innovative targeted radiopharmaceutical drugs for cancer, today announced a $108 million Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.
  • The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated, said Ken Song, M.D., president and CEO of RayzeBio.
  • With over $258 million of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.
  • RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes.